Evaluating the safety and efficacy of nirmatrelvir-ritonavir therapy in pregnant women with COVID-19: a systematic review and meta-analysis

被引:0
|
作者
Hassan, Omar [1 ,2 ]
Elbhairy, Aya Abdulkarim [2 ]
Siam, Aya Magdy [2 ]
Abdelwahab, Tasneem [2 ]
Hamad, Albraa Ashraf [2 ]
Mahmoud, Omar Ehab [2 ]
Nabeh, Omnia Azmy [2 ]
机构
[1] Negida Acad, Med Res Grp Egypt, Arlington, MA USA
[2] Cairo Univ, Kasr Alainy Fac Med, Cairo, Egypt
关键词
COVID-19; Fetal; Neonates; Nirmatrelvir-Ritonavir; Pregnancy; SARS-COV2; CORONAVIRUS DISEASE 2019; OUTCOMES;
D O I
10.1007/s00228-025-03808-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PurposePregnant women are at heightened risk for severe COVID-19 outcomes. However, treatment options during pregnancy remain limited due to concerns over their safety and efficacy.MethodsThis systematic review and meta-analysis assessed the safety and efficacy of nirmatrelvir-ritonavir in pregnant women diagnosed with mild-to-moderate COVID-19. The analysis focused on cases where the treatment was initiated within five days of symptom onset. A single-arm meta-analysis was performed to comprehensively evaluate outcomes across maternal, delivery, and neonatal domains.ResultsIn line with PRISMA guidelines, six studies involving a total of 427 pregnant patients were included in the analysis. Hospitalization was reported in 2% of patients (95% CI: 1%-5%), with low heterogeneity across studies (I2 = 21.9%). Drug discontinuation and new-onset gestational diabetes (NOGDM) had a pooled estimate of 0.7% (95% CI: 3% to 15%) and 4.0% (95% CI: 1% to 16%), respectively, with substantial heterogeneity (I2 = 64.7% and 66.5%), respectively. New-onset gestational hypertension (NOGHTN) had a pooled estimate of 4% (95% CI: 1% to 26%), with considerable heterogeneity (I2 = 78.81%). For neonatal outcomes, the pooled estimate for birth weight was 3186 g (95% CI: 3123-3248 g; I2 = 0%), and no maternal or neonatal deaths were reported across the included studies.ConclusionNirmatrelvir-ritonavir appears safe and effective for mild-to-moderate COVID-19 in pregnant women, with low rates of hospitalization and adverse maternal outcomes. Larger, randomized studies are crucial to confirm these findings and ensure safety in diverse populations.
引用
收藏
页码:495 / 506
页数:12
相关论文
共 50 条
  • [1] Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis
    Cheema, Huzaifa A. A.
    Jafar, Uzair
    Sohail, Aruba
    Shahid, Abia
    Sahra, Syeda
    Ehsan, Muhammad
    Athar, Farwa
    Shah, Jaffer F.
    Sah, Ranjit
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [2] Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis
    Amani, Bahman
    Akbarzadeh, Arash
    Amani, Behnam
    Shabestan, Rouhollah
    Khorramnia, Saeed
    Navidi, Zia
    Rajabkhah, Kourosh
    Kardanmoghadam, Vida
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (06)
  • [3] Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis
    Amani, Behnam
    Amani, Bahman
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [4] Nirmatrelvir-ritonavir for COVID-19
    McDonald, Emily G.
    Lee, Todd C.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (06) : E218 - E218
  • [5] Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis
    Tian, Fangyuan
    Chen, Zhaoyan
    Feng, Qiyi
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (04)
  • [6] Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
    Cohen, Myron S.
    Brown, Elizabeth R.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (12) : 1672 - 1673
  • [7] Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
    Amani, Behnam
    Amani, Bahman
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (07) : 547 - 555
  • [8] Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
    Alhumaid, Saad
    Al Mutair, Abbas
    Al Alawi, Zainab
    Alhmeed, Naif
    Zaidi, Abdul Rehman Zia
    Tobaiqy, Mansour
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2020, 5 (04)
  • [9] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [10] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549